Therefore, the β-catenin signalling pathway is another potential target for colon cancer treatment.11 Here, we demonstrate that MEK inhibitor sensitivity was driven by the PIK3CA genotype in KRAS mutant colon cancer cells. Here, MAP2K7 is linked to colonic neoplasm.